Mirati’s Adagrasib Takes The Lead Among KRAS G12C Inhibitors In CRC
Monotherapy, Combo Data Outshine Amgen’s Lumakras
Mirati's adagrasib may pull out from behind Amgen's Lumakras lead in lung cancer with an accelerated approval in colorectal cancer • Source: Alamy 
